Who are Oral chenodeoxycholic acid stimulation's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CDCA Weight-Based Dose TID.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oral-chenodeoxycholic-acid-stimulation.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Oral chenodeoxycholic acid stimulation — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oral chenodeoxycholic acid stimulation (Oral chenodeoxycholic acid stimulation) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bile acid receptor agonist. Area: Hepatology / Gastroenterology.

marketed Bile acid receptor agonist FXR (farnesoid X receptor), TGR5 Hepatology / Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Oral chenodeoxycholic acid stimulation (Oral chenodeoxycholic acid stimulation) — Lars Kristian Munck. Chenodeoxycholic acid is a bile acid that activates farnesoid X receptor (FXR) and TGR5 signaling pathways to regulate bile acid metabolism and reduce cholestasis.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Oral chenodeoxycholic acid stimulation TARGET	Oral chenodeoxycholic acid stimulation	Lars Kristian Munck	marketed	Bile acid receptor agonist	FXR (farnesoid X receptor), TGR5
CDCA Weight-Based Dose TID	CDCA Weight-Based Dose TID	Mirum Pharmaceuticals, Inc.	phase 3	Bile acid receptor agonist	FXR (farnesoid X receptor), TGR5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bile acid receptor agonist class)

Lars Kristian Munck · 1 drug in this class
Mirum Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oral chenodeoxycholic acid stimulation — Competitive Intelligence Brief. https://druglandscape.com/ci/oral-chenodeoxycholic-acid-stimulation. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab